73.44
price up icon2.00%   1.44
after-market Handel nachbörslich: 74.00 0.56 +0.76%
loading
Schlusskurs vom Vortag:
$72.00
Offen:
$71.71
24-Stunden-Volumen:
2.44M
Relative Volume:
1.45
Marktkapitalisierung:
$13.03B
Einnahmen:
$342.96M
Nettoeinkommen (Verlust:
$-864.29M
KGV:
-13.23
EPS:
-5.55
Netto-Cashflow:
$-636.03M
1W Leistung:
-4.09%
1M Leistung:
-9.94%
6M Leistung:
+0.58%
1J Leistung:
+179.24%
1-Tages-Spanne:
Value
$70.30
$73.45
1-Wochen-Bereich:
Value
$70.30
$79.12
52-Wochen-Spanne:
Value
$21.92
$84.91

Insmed Inc Stock (INSM) Company Profile

Name
Firmenname
Insmed Inc
Name
Telefon
908-977-9900
Name
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Name
Mitarbeiter
1,271
Name
Twitter
@insmed
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
INSM's Discussions on Twitter

Vergleichen Sie INSM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
INSM
Insmed Inc
73.44 13.03B 342.96M -864.29M -636.03M -5.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Insmed Inc Stock (INSM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-25 Eingeleitet RBC Capital Mkts Outperform
2024-04-23 Eingeleitet Truist Buy
2024-02-15 Eingeleitet Wolfe Research Outperform
2023-12-08 Eingeleitet Wells Fargo Overweight
2023-11-20 Fortgesetzt JP Morgan Overweight
2023-07-26 Eingeleitet Guggenheim Buy
2022-12-09 Eingeleitet Mizuho Buy
2022-12-07 Eingeleitet Barclays Overweight
2022-11-18 Eingeleitet BofA Securities Buy
2022-04-27 Eingeleitet Goldman Buy
2021-12-06 Eingeleitet JP Morgan Overweight
2021-10-19 Fortgesetzt Monness Crespi & Hardt Buy
2021-10-19 Fortgesetzt Morgan Stanley Overweight
2021-10-08 Eingeleitet Cantor Fitzgerald Overweight
2021-04-26 Fortgesetzt Credit Suisse Outperform
2020-12-17 Eingeleitet Berenberg Buy
2020-10-12 Fortgesetzt Stifel Buy
2019-09-03 Eingeleitet Goldman Buy
2019-04-09 Bestätigt H.C. Wainwright Buy
2019-02-15 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2019-01-17 Hochstufung Goldman Neutral → Buy
2019-01-02 Eingeleitet Canaccord Genuity Buy
2018-08-06 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2018-07-23 Eingeleitet Goldman Neutral
2018-04-23 Hochstufung Credit Suisse Neutral → Outperform
2018-03-21 Eingeleitet Morgan Stanley Overweight
2018-01-18 Eingeleitet Credit Suisse Neutral
2017-09-05 Bestätigt Evercore ISI Outperform
2017-08-17 Eingeleitet Evercore ISI Outperform
2017-07-11 Eingeleitet Robert W. Baird Outperform
2016-03-15 Eingeleitet Stifel Buy
2015-11-09 Herabstufung UBS Buy → Neutral
2015-10-06 Bestätigt H.C. Wainwright Buy
2015-06-09 Eingeleitet Citigroup Neutral
2014-03-26 Bestätigt HC Wainwright Buy
Alle ansehen

Insmed Inc Aktie (INSM) Neueste Nachrichten

pulisher
09:52 AM

Insmed Incorporated (INSM): Insiders Were Dumping in Q1 2025 - Insider Monkey

09:52 AM
pulisher
Mar 25, 2025

Is Insmed Incorporated (INSM) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

Breakthrough Data: Insmed's Phase 3 Trial Could Transform Bronchiectasis Treatment - Stock Titan

Mar 25, 2025
pulisher
Mar 22, 2025

Insmed’s SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Canada

Mar 22, 2025
pulisher
Mar 22, 2025

Insmed’s SWOT analysis: rare disease biotech stock poised for growth - Investing.com

Mar 22, 2025
pulisher
Mar 20, 2025

Insmed reports preclinical data on INS-1201 for DMD - BioWorld MedTech

Mar 20, 2025
pulisher
Mar 19, 2025

Insmed CEO William Lewis sells $1.97 million in stock By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

Insmed’s stock should triple after positive drug trial data, analyst says - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

H.C. Wainwright maintains Buy on Insmed stock, $90 target By Investing.com - Investing.com Canada

Mar 19, 2025
pulisher
Mar 19, 2025

Insmed CEO William Lewis sells $1.97 million in stock - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Expert Outlook: Insmed Through The Eyes Of 13 Analysts - Benzinga

Mar 19, 2025
pulisher
Mar 19, 2025

RBC maintains Outperform on Insmed stock, price target at $100 By Investing.com - Investing.com Canada

Mar 19, 2025
pulisher
Mar 18, 2025

Insmed Incorporated (INSM): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance

Mar 18, 2025
pulisher
Mar 15, 2025

15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey

Mar 15, 2025
pulisher
Mar 12, 2025

Truist maintains Buy on Insmed stock, sees PAH data as positive - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

US Bancorp DE Boosts Holdings in Insmed Incorporated (NASDAQ:INSM) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Truist maintains Buy on Insmed stock, sees PAH data as positive By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 11, 2025

Insmed at Leerink Global Healthcare Conference: Optimism for Brenzo’s Launch By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 11, 2025

Insider Sell: Roger Adsett Sells 42,975 Shares of Insmed Inc (IN - GuruFocus.com

Mar 11, 2025
pulisher
Mar 11, 2025

Insmed at Leerink Global Healthcare Conference: Optimism for Brenzo’s Launch - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Smartleaf Asset Management LLC - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Citizentribune

Mar 10, 2025
pulisher
Mar 10, 2025

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -March 10, 2025 at 08:01 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Insmed Expands Team with Stock Options Grant to 18 New Hires - StockTitan

Mar 10, 2025
pulisher
Mar 08, 2025

UBS Group Raises Insmed (NASDAQ:INSM) Price Target to $110.00 - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Insmed’s Strategic Growth and Promising Pipeline Drive Buy Rating - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

UBS raises Insmed stock price target to $110 By Investing.com - Investing.com UK

Mar 06, 2025
pulisher
Mar 06, 2025

UBS raises Insmed stock price target to $110 - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

Insmed CEO Lewis sells $1.99 million in stock By Investing.com - Investing.com Australia

Mar 06, 2025
pulisher
Mar 05, 2025

Insmed CEO Lewis sells $1.99 million in stock - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Amalgamated Bank Boosts Stake in Insmed Incorporated (NASDAQ:INSM) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Sanctuary Advisors LLC Acquires 464 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World

Mar 05, 2025
pulisher
Mar 01, 2025

Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 - Star Tribune

Mar 01, 2025
pulisher
Mar 01, 2025

RBC Capital starts Insmed at Outperform on brensocatib launch momentum - MSN

Mar 01, 2025
pulisher
Mar 01, 2025

Guggenheim Reaffirms Buy Rating for Insmed (NASDAQ:INSM) - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Investor Network: Insmed Incorporated to Host Earnings Call - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 27, 2025

Major Public Health Interest? Scholar, Insmed & Soleno Ask EMA To Fast-Track Their Products - insights.citeline.com

Feb 27, 2025
pulisher
Feb 27, 2025

Truist Financial Corp Boosts Stake in Insmed Incorporated (NASDAQ:INSM) - Defense World

Feb 27, 2025
pulisher
Feb 27, 2025

Insmed (NASDAQ:INSM) Now Covered by Royal Bank of Canada - MarketBeat

Feb 27, 2025
pulisher
Feb 26, 2025

Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates - MSN

Feb 26, 2025
pulisher
Feb 26, 2025

RBC Capital Initiates Coverage of Insmed (LSE:0JAV) with Outperform Recommendation - Nasdaq

Feb 26, 2025
pulisher
Feb 26, 2025

Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says - Benzinga

Feb 26, 2025
pulisher
Feb 25, 2025

RBC Capital sets $100 price target on Insmed stock with Outperform rating - Investing.com Canada

Feb 25, 2025
pulisher
Feb 25, 2025

RBC Capital Initiates Coverage of Insmed (INSM) with Outperform Recommendation - MSN

Feb 25, 2025
pulisher
Feb 25, 2025

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Feb 25, 2025
pulisher
Feb 25, 2025

Insmed to Benefit From Strong Launch of Brensocatib for Lung Disease, RBC Says -February 25, 2025 at 12:09 pm EST - Marketscreener.com

Feb 25, 2025

Finanzdaten der Insmed Inc-Aktie (INSM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Insmed Inc-Aktie (INSM) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Lewis William
Chair and CEO
Mar 17 '25
Option Exercise
22.76
18,750
426,750
352,936
Lewis William
Chair and CEO
Mar 17 '25
Option Exercise
10.85
6,830
74,106
240,754
Lewis William
Chair and CEO
Mar 17 '25
Sale
77.03
18,750
1,444,241
334,186
Lewis William
Chair and CEO
Mar 17 '25
Sale
77.04
6,830
526,179
233,924
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Kapitalisierung:     |  Volumen (24h):